Merck & Co., Inc. (0QAH.IL)
| Previous close | 129.30 |
| Open | 130.39 |
| Bid | 127.60 x N/A |
| Ask | 134.40 x N/A |
| Day's range | 130.07 - 131.77 |
| 52-week range | 99.15 - 133.08 |
| Volume | |
| Avg. volume | 195,429 |
| Market cap | 333.176B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 107.62 |
| EPS (TTM) | 1.22 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 2.92 (2.83%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
BenzingaMerck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
ZacksMerck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
